CpG‐based nanovaccines bolster ovarian cancer immunotherapy via the Gbp2‐Pin1‐NFkB pathway‐mediated reprogramming of tumor‐associated macrophages (TAMs). This evidence concerns the gene NFKB1 and neoplasm.